LP
XFOR icon

LMR Partners’s X4 Pharmaceuticals XFOR Stock Holding History

LMR Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-338
Closed -$66K – 1218
2021
Q2 		$66K Buy
+338
New +$85K ﹤0.01% 945

Other funds holding XFOR

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

LMR Partners's XFOR Position: Q3 2021 in Review

LMR Partners sold out of X4 Pharmaceuticals (XFOR) in Q3 2021, closing a stake of 338 shares — an estimated $66K sold.

LMR Partners first reported a position in XFOR in Q2 2021 and held it in 1 quarter. The position peaked at $66K in Q2 2021. 51 funds tracked by Wall St. Rank hold XFOR as of Q3 2021.

  • LMR Partners reported no remaining X4 Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • LMR Partners sold 338 X4 Pharmaceuticals shares in Q3 2021, an estimated $66K.
  • LMR Partners first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • LMR Partners's X4 Pharmaceuticals position peaked at $66K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.